Study Title and Description
Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.
Key Questions Addressed
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.|
|Author||Ensrud KE., Stock JL., Barrett-Connor E., Grady D., Mosca L., Khaw KT., Zhao Q., Agnusdei D., Cauley JA.|
|Country||Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center, Minneapolis, Minnesota, USA. ensru001@.umn.edu|
Pubmed ID: 17892376
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.